Introduction
Personalized medicine through molecular pharmacogenetics is one of the major future goals in clinical medicine. Especially in psychopharmacology, therapy is time-and cost intensive and the variability of treatment response a crucial problem. Genotyping needs to be accomplished only once in a lifetime and may be useful in improving therapy with existing drugs such as olanzapine, an important atypical antipsychotic. The polymorphisms relevant under real-life conditions have to be identified before the establishment of routine genotyping.
Both response and side effects may result from interindividual pharmacodynamic differences at the receptor level or from pharmacokinetic differences in the body's metabolism of the drug. Therefore, apart from nongenetic factors, the relevant polymorphisms in genes coding for receptors targeted by antipsychotic drugs or in genes involved in the metabolism and bioavailability of antipsychotic medications may be of relevance.
Olanzapine has a broad receptor-binding profile with high in vivo affinity for the dopaminergic (DRD2) and serotonergic (5-HTRA) receptors in the CNS accounting for its pharmacological effects. [1] [2] [3] Several polymorphisms in dopaminergic and serotonergic receptors have already been linked to clinical outcome of atypical antipsychotics. [4] [5] [6] [7] Moreover, a promising new serotonergic polymorphism has been linked to clinical outcome of the antidepressant citalopram, 5-HTR2A intron 2 G/A (rs7997012). 8 Candidate gene studies on antipsychotic-induced weight gain produced significant findings in the 5-HTR2C, GNB3 and ADR2A receptor genes. [9] [10] [11] [12] [13] [14] CYP1A2 and, less significantly, CYP2D6 are involved in the metabolism of olanzapine. 15, 16 The CYP1A2*1F (À163A) polymorphism (rs762551) has been associated with higher enzyme inducibility and higher clearance of CYP1A2 substrates such as melatonin 17 or caffeine in Caucasian smokers. 18, 19 We investigated whether the CYP1A2*1F polymorphism has a significant impact on olanzapine serum concentration in a clinical setting. We examined further whether this polymorphism, the olanzapine serum concentrations or pharmacodynamic polymorphisms are associated with treatment response or side effects including acute weight gain.
Results

CYP1A2*1F, serum concentrations and clinical outcome
Steady-state serum samples were available for 73 patients (36 men, 37 women; age 19-76 years; 30 smokers). Of these, 41 were homozygous for the highly inducible CYP1A2*1F (À163A) genotype, 27 were heterozygotes and 5 homozygous for the CYP1A2*1A (À163C) genotype (allele frequencies of 75% for the A-allele and 25% for the C-allele). Of the patients, 34 had depressive disorders (F3 diagnosis), 32 schizophrenic disorders (F2 diagnosis) and 7 another F-diagnosis according to ICD-10. These patients were treated with olanzapine doses ranging from 2.5 to 30 mg per day. Serum concentrations ranged from below the limit of quantification (o2.5 ng ml À1 ) to 87.4 ng ml À1 with a linear dose-serum concentration relationship (r ¼ 0.75, Po0.001).
The mean baseline characteristics of the serum cohort and of the whole study population are given in Table 1 .
Possible covariates were examined with regard to their influence on dose-normalized or dose-/body weight-normalized serum concentrations. No influence was observed for baseline characteristics (age, height, weight, baseline severity of illness, gender and diagnosis). Elderly women (aged 460 years) received on average lower doses (11 ± 7 vs others 15±8 mg olanzapine, Mann-Whitney U-test, P ¼ 0.079) but their normalized serum concentrations were similar compared to all other patients.
The possible influence of comedication was evaluated considering CYP1A2*1F genotype and smoking status. There were insufficient data to support statistical evaluation for most single drugs. Thus, comedicated drugs were rated as substrates, inhibitors and inducers of cytochrome P450 isoenzymes according to the Cytochrome P450 Drug Interaction Table. 20 Only five patients received no comedication whereas comedication in all other patients included lorazepam ( The six patients comedicated with the inducer carbamazepine had significantly decreased normalized serum concentrations (on average only half of those without carbamazepine comedication; see Table 2 ). Three patients were smokers (two CYP1A2*1F/*1F genotyped) and three nonsmokers (two CYP1A2*1F/*1F genotyped). Smokers received significantly higher doses of olanzapine and displayed lower normalized olanzapine concentrations (on average approximately three-quarters that of nonsmokers; see Table 2 ). Patients with the CYP1A2*1F/*1F genotype had also significantly lower normalized olanzapine concentrations compared to homo-and heterozygote carriers of CYP1A2*1A (on average approximately three-quarters of other genotypes). A post hoc analysis with Bonferroni's test for pairwise comparisons was significant for the 41 CYP1A2*1F/*1F vs the 27 CYP1A2*1F/*1A carriers, but not vs the small group of 5 CYP1A2*1A/*1A carriers (see Table 2 ; Figure 1 ). For the further combined evaluation of genotype and inducers, the homo-and heterozygote carriers of CYP1A2*1A were evaluated together as 'CYP1A2*1A carriers'.
The difference in dose-or dose-/body weight-normalized olanzapine concentration for the different CYP1A2 genotypes was not explainable by baseline differences or CYP1A2 inducers alone (carbamazepine, smoking). As shown in Figure 2 , CYP1A2*1F/*1F patients who did not take any inducers (mean±s.d., 101±46 ng ml À1 per mg kg À1 , n ¼ 19) had 22% lower concentrations compared to homo-or heterozygote carriers of CYP1A2*1A without induction (130±37 ng ml À1 per mg kg À1 , n ¼ 21). Similarly, patients who carried the inducible CYP1A2*1F/*1F genotype and who were under the influence of inducers (tobacco smoke, carbamazepine) had a 20% lower mean dose-/body weightnormalized serum concentrations (75 ± 52 ng ml À1 per mg kg À1 , n ¼ 22) compared to CYP1A2*1A carriers with induction (94±52 ng ml À1 per mg kg À1 , n ¼ 11). The difference was significant across the four groups (analysis of variance (ANOVA), P ¼ 0.001 and P ¼ 0.002 for dose-and dose-/body weight-normalized concentrations, respectively) and remained significant after Bonferroni's post hoc analysis for pairwise comparisons between CYP1A2*1A vs CYP1A2*1F/*1F plus inducers (P ¼ 0.0004 and P ¼ 0.001, respectively).
In 4 of 73 serum samples, olanzapine was below the lower limit of quantification (LLOQ o2.5 ng ml À1 ). A second examination was done without these patients to exclude the possibility that noncompliance influenced the abovegiven relationships, but the relationships between genotype and/or inducers and dose-or dose-/body weight-normalized concentrations remained significant.
To take all possible covariates into account, a multiple linear regression analysis was used to detect correlations between normalized olanzapine concentrations and several factors including age, baseline height and weight, gender, smoking, diagnosis, CYP1A2*1F genotype and CYP1A2- A post hoc analysis with Bonferroni's test for pairwise comparisons was significant for CYP1A2*1F/*1F vs CYP1A2*1A/*1F (P ¼ 0.030 for dose-normalized and P ¼ 0.038 for dose-/body weight-normalized olanzapine concentrations).
Influence of CYP1A2*1F on olanzapine treatment B Laika et al relevant comedication. CYP1A2*1F/*1F genotype (standardized partial correlation coefficients beta ¼ À0.24; P ¼ 0.026 and beta ¼ À0.29; P ¼ 0.005 for dose-and dose-/body weight-normalized concentrations, respectively) and comedication with carbamazepine (beta ¼ À0.28; P ¼ 0.010 and beta ¼ À0.31; P ¼ 0.009, respectively) were significantly correlated with normalized serum concentrations. The correlation with dose-normalized concentrations reached statistical significance (beta ¼ À0.24, P ¼ 0.027) whereas the correlation between smoking and dose-/body weight-normalized concentrations just missed out (beta ¼ À0.20, P ¼ 0.063). The coefficient of determination r 2 indicated that the concentration variation can be explained by the included factors (19 and 23%, respectively) .
No response or side-effect differences could be detected for CYP1A2*1F genotypes. Side effects were not correlated with olanzapine concentrations. Yet patients with schizophrenic disorders showed better improvement of paranoid and depressive symptoms after 4 weeks of treatment if their steady-state olanzapine concentrations were higher (n ¼ 31 available, paranoid depression scale (PDS) self-rating score difference 4 week-baseline: paranoid subscale Spearman's r ¼ 0.5, P ¼ 0.026 and depressive subscale score r ¼ 0.5, P ¼ 0.006). This was confirmed by the CGI rating of the treating psychiatrist: higher olanzapine concentrations were correlated with lower severity of illness after 4 weeks (Spearman's r ¼ 0.4, P ¼ 0.049), whereas no significant correlation was seen for the baseline rating (P40.2). No such relationship was seen in patients with affective disorders or other diagnoses.
Genotypes and side effects
Apart from dopaminergic receptors, the atypical antipsychotic olanzapine targets serotonin receptors (in particular 5-HTR2A, 5-HTR2C and 5-HTR1A). Except for the 5-HTR2A intron 2 (rs7997012 G/A) polymorphism, no significant associations with response or side-effect data were found for the examined dopaminergic or serotonergic polymorphisms (DRD2 À141Ins/Del, DRD2 Taq1A, DRD3 Ser9Gly, 5-HTRA T102C and 5-HT6 T267C).
Side-effect data were available for 95 patients without the potentially interfering comedication of serotonin reuptake inhibitors whose efficacy is partly mediated by the effect on the 5-HTR2A. Patients with AA genotype suffered from significantly more side effects compared to carriers of the G-allele. Mean ± s.d. side-effect (Dosage Record and Treatment Emergent Symptoms Scale; DOTES) sum scores were 1.9±2.8 for the 34 GG carriers, 2.1±2.2 for the 49 GA Figure 1 Impact of CYP1A2*1F genotype on olanzapine serum concentrations (corrected for dose and weight). The steady-state concentrations after 4 weeks of treatment of 73 patients classified according to CYP1A2*1F genotype. Lines denote the mean values with 121 and 117 ng ml À1 per mg kg À1 for the 5 and 27 homo-and heterozygote CYP1A2*1A carriers, respectively, and 87 ng ml À1 per mg kg À1 for CYP1A2*1F/*1F carriers. The difference in dose-/body weight-normalized olanzapine concentrations was significant across the three groups (analysis of variance (ANOVA), P ¼ 0.028) and remained significant after post hoc Bonferroni's testing for pairwise comparisons between CYP1A2*1A/*1F vs CYP1A2*1F/*1F plus inducers (P ¼ 0.038). for the 22 patients with inducible CYP1A2*1F/*1F genotype plus inducers. The difference in dose-/body weight-normalized olanzapine concentrations was significant across the four groups (analysis of variance (ANOVA), P ¼ 0.002) and remained significant after post hoc Bonferroni's testing for pairwise comparisons between CYP1A2*1A vs CYP1A2*1F/*1F plus inducers (P ¼ 0.001).
carriers and 3.8±3.0 for the 12 AA carriers (P ¼ 0.057 for AA vs GA and P ¼ 0.018 with mean standardized effect size of 0.7 for AA vs GG). Baseline characteristics (age, height, weight, baseline severity of illness, smoking habits, diagnosis and gender, P values X0.3) were similar between the three genotypes including olanzapine dosage (12 ± 6 vs 12 ± 7 and 11 ± 5 mg for GG vs GA and AA, respectively, P ¼ 0.98). The most prescribed comedicated drug, mirtazapine, was evenly distributed (17 of 37 GG carriers, 22 of 49 GA carriers and 6 of 12 AA carriers, P ¼ 0.88).
Mirtazapine blocks serotonin receptors (5-HTR2 and 5-HTR3). 21 Thus, it could interfere with the effects of any 5-HTR2A functional variation. 22 Indeed, the 45 patients with mirtazapine comedication (n ¼ 45) had similar side effects across three 5-HTR2A intron 2 genotypes. Mean±s.d. DOTES sum scores were 2.5 ± 3.5 for the 17 GG carriers, 1.9 ± 1.9 for the 22 GA carriers and 2.7 ± 3.3 for the 6 AA carriers (P values 40.7).
In the group without antidepressant comedication (n ¼ 50), an almost linear increase of side-effect score was seen. DOTES sum scores increased from 1.2 ± 1.7 for the 17 GG carriers, 2.3±2.4 for the 27 GA carriers and 5.0±2.5 for the 6 AA carriers (mean standardized effect size of 1.9 and P ¼ 0.002 for AA vs GG; mean standardized effect size of 1.1 and P ¼ 0.018 for AA vs GA; see Figure 3 ). Only 25% (11/44) of G-allele carriers, but 83% (5/6) of the patients with AA genotype had moderate/marked side effects (Fisher's exact test, P ¼ 0.0098, odds ratio of 15 with a 95% confidence interval of 2-143). Baseline characteristics and olanzapine doses (15 ± 7 vs 14 ± 7 and 12 ± 6 mg for GG vs GA and AA, respectively, P ¼ 0.6) were comparable between the different 5-HTR2A intron 2 genotypes in the subgroup. No further influence of any comedication was detectable against the background noise of a naturalistic setting.
Genotypes and weight gain
Weight gain is a severe problem in therapy of mood and schizophrenic disorders. The patients receiving only olanzapine without comedication known for its influence on weight (amitriptyline, mirtazapine, lithium, valproic acid, clozapine, risperidone, typical antipsychotics 23 ) were analyzed for acute weight gain after 4 weeks. Patients homo-or hemizygous for the 5-HTR2C À759 C-allele had a significantly higher risk of weight gain. The 39 CC or C-allele carriers gained on average 3.9% of their baseline weight within the 4 weeks of treatment, whereas the 17 T-allele carriers gained only 0.9% (P ¼ 0.011 with an effect size of 0.7; see Table 3 ).
Multiple regression analysis was performed to take into account possible additional influence factors besides the examined genetic variants (olanzapine dose, baseline weight or BMI, age, gender, diagnosis, smoking status, response, treatment naiveness). This analysis identified CGI(2) improvement (standardized partial correlation coefficients beta ¼ À0.41; P ¼ 0.002) and the homo-or hemizygous 5-HTR2C À759C genotype (beta ¼ 0.35; P ¼ 0.006) as significant influence factors. The coefficient of determination r 2 ¼ 0.27 indicates that 27% of the weight variation can be explained by genotype and treatment response. The ADR2A Figure 3 Side effects under olanzapine therapy for each genotype of the 5-HTR2A intron 2 G/A polymorphism. Side effects (Dosage Record and Treatment Emergent Symptoms Scale (DOTES) sum score) were evaluated for the 50 patients without antidepressant comedication (17 GG, 27 GA and 6 AA). Data are presented by mean ± s.d. Average DOTES sum scores were 1.2 for GG, 2.3 for GA and 5.0 for AA with P ¼ 0.002 for AA vs GG, P ¼ 0.018 for AA vs GA and P ¼ 0.104 for GA vs GG (Mann-Whitney U test). Table 3 Short-term weight gain for 5-HTR2C C-759T polymorphism under olanzapine therapy
5-HTR2C C-759T
C/T, T/T or T C/C or C Total P value n ¼ 17 n ¼ 39 n ¼ 56 The absolute change of body weight or BMI and relative body weight change from baseline to the endpoint after 4 weeks of olanzapine treatment was significantly higher for 5-HTR2C À759 C/C-homozygotes and C-hemizygotes vs T-allele carriers (Mann-Whitney U test P ¼ 0.008, 0.009 and P ¼ 0.011, respectively).
Influence of CYP1A2*1F on olanzapine treatment B Laika et al C-1291G genotype (beta ¼ 0.21; P ¼ 0.090) missed inclusion in the model. No trend was observed for GNB3 C825T.
Discussion
CYP1A2*1F, serum concentrations and clinical outcome
Olanzapine serum concentrations showed high interindividual variability as reported previously. 1 The highly variable CYP1A2 metabolism and the chosen clinical setting with a heterogeneous patient cohort with different comedications and comorbidities provide reasonable explanations for this. It is well known that CYP1A2 activity is induced by tobacco smoke, grilled meat, cruciferous vegetables or drugs such as omeprazole and inhibited by other drugs such as fluvoxamine, ciprofloxacin or oral hormone replacement therapy and contraceptives. 20 The effect of smoking and the potent inducer carbamazepine was also found in our cohort in accordance with previous reports. 16, [24] [25] [26] [27] [28] [29] [30] [31] [32] No effect of age, gender or other drugs was observed in our cohort. Previous reports are contradictory on these factors. 16, 24, 25, 28, 29 This study was not designed as an interaction study and the majority of patients were on polypharmacy. Thus, smaller effects may have been missed.
Moreover, the CYP1A2*1F (À163A) polymorphism was reported to affect the inducibility of CYP1A2. In our study population, CYP1A2*1F/*1F genotype alone resulted in a 22% reduction of dose-/body weight-normalized olanzapine serum concentrations compared to CYP1A2*1A carriers (both without induction). This effect was independent of the well-known effect of inducing agents (tobacco smoke, carbamazepine, on average À28% in CYP1A2*1A carriers and À26% in CYP1A2*1F/*1F carriers). Consistently, patients with the CYP1A2*1F/*1F genotype taking inducers had 22% lower concentrations compared to CYP1A2*1A carriers taking inducers.
Our findings suggest an independent effect of this polymorphism on constitutive expression levels or catalytic activity instead of mere higher inducibility. This is surprising as up to now an effect of this polymorphism was mainly reported in combination with inducing agents. 33, 34 In one study in Japanese patients, olanzapine concentrations were not affected by CYP1A2 polymorphisms but only by smoking. 35 This finding, however, may not be applicable for Caucasians due to further interethnic genetic differences as discussed previously. 19 The CYP1A2*1F (À163A) polymorphism was associated with higher clearance of the CYP1A2 substrate caffeine in Caucasian smokers 18, 19 but not in nonsmokers or in Korean smokers. Despite the close concordance between caffeine and olanzapine clearance, 26, 36 different characteristics in the examined study populations-steady-state olanzapine concentrations in patients vs single-dose administration in healthy volunteers-may have led to different results.
Moreover, the results of a study on the CYP1A2 substrate melatonin also suggested an independent effect of CYP1A2*1F alone on melatonin concentrations in 24 healthy volunteers of Caucasian origin. 17 Yet this independent effect was not observed in a clinical trial on clozapine concentrations, another CYP1A2 substrate. 37 On the contrary, an effect of the CYP1A2*1F genotype alone was detected in a previous study on the risk for tardive dyskinesia, a severe and potentially irreversible side effect, under treatment with typical antipsychotics such as haloperidol which is also a CYP1A2 substrate. The risk was lower for CYP1A2*1F carriers in general and was most pronounced in CYP1A2*1F carriers who were smokers. 38 These varying findings for a number of CYP1A2 substrates may be explained by different binding and affinity at the catalytic site of CYP1A2 or alternative metabolic pathways. For instance, clozapine is, in contrast to olanzapine, also metabolized by CYP3A4. 15 Theoretically, the observed effect may be due to intake of other, unknown inducers. Indeed, it has been reported that certain dietary chemicals, for example, those which are contained in broccoli, brussels sprouts or char-grilled meat, 20, 39 have CYP1A2 inducing features. Moreover, the CYP1A2 substrate caffeine might have an influence-there have been several reports that ingestion or removal of caffeine containing beverages influenced concentrations of the CYP1A2 substrate clozapine. 40 Our patients, however, had been hospitalized and were on a standard diet which did not contain major amounts of these foods. An unusual exposure to and influence of alimentary inducers is, therefore, unlikely.
Thus, CYP1A2*1F genotyping could be useful as additional predictor of CYP1A2 activity and olanzapine concentrations. It may help to guide clinical treatment decisions, given the fact that olanzapine serum concentrations correlated with treatment response in patients with schizophrenic disorders (F2 diagnosis) in accordance with previous reports. 1 Our naturalistic clinical setting with a heterogeneous patient cohort emphasizes the clinical relevance of this finding. Noteworthy is the strong relationship between olanzapine concentrations and improvement of depressive symptoms in schizophrenic patients. Olanzapine is known for its effect on affective and depressive symptomatology in acute psychotic patients. Side effects and weight gain, however, seem to be more influenced by serotonergic polymorphisms than by olanzapine concentrations or dose as discussed below.
Genotypes and side effects
Olanzapine targets dopamine receptors and serotonin receptors particularly 5-HTR2A, 5-HTR2C and 5-HTR1A receptors. 3 Several polymorphisms have been examined for associations with clinical outcome under antipsychotic therapy. Some significant associations were reported especially for 5-HTR2A T102C, but a number of nonreplicating studies do not allow any definite conclusions to be drawn. [4] [5] [6] 41, 42 The effects on clinical outcome were mostly reported to be modest and may not be large enough to be of clinical relevance. Accordingly, no associations were detected in our naturalistic setting for dopaminergic and most serotonergic polymorphisms (DRD2 À141Ins/Del, DRD2 Taq1A, DRD3 Ser9Gly, 5-HT2A T102C, 5-HT6 T267C,  5-HT2C C-759T, ADR2A C-1291G, GNB3 C825T) .
In a recent study with 1953 depressive patients, participants that were 5-HTR2A (rs7997012) AA homozygous had an 18% reduced absolute risk of nonresponse to citalopram treatment, compared with those homozygous for the other allele. 8 As shown by our findings, this polymorphism may also influence the clinical outcome of other drugs, which are effective via this receptor. In our population, patients with the 5-HTR2A intron 2 (rs7997012) AA genotype suffered from more side effects compared to carriers of the GA or GG genotype. The wide distribution of the 5-HTR2A serotonin receptor not only in the CNS, but also in the periphery (for example, on smooth muscle cells in the gut and vasculature) may explain the potential for side effects observed in this study. The differences in side effects were more pronounced in patients without mirtazapine comedication (P ¼ 0.002 for AA vs GG and P ¼ 0.018 for AA vs GA). Mirtazapine also blocks the 5-HTR2A receptor 21 and might interfere with the effects of any 5-HTR2A functional variation. 22 We evaluated only side effects most likely caused by olanzapine and excluded comedications whose mode of action suggests interference. Yet we cannot fully exclude the possible influence of comorbidities or comedication, which may lead to false-positive or -negative observations.
Genotypes and weight gain
Weight gain is a severe problem in therapy with olanzapine. 43 Interindividual genetic differences have been discussed as contributing to antipsychotic-induced weight gain besides nongenetic factors. 44, 45 Olanzapine has a broad receptor-binding profile including adrenoceptors, dopaminergic and serotonergic receptors amongst others, which are possible candidates to explain part of the weight gain. The exact underlying pharmacodynamic mechanisms involved in antipsychotic-induced weight gain have not been fully elucidated. Candidate gene studies have produced significant findings in the 5-HTR2C, GNB3, ADR2A and DRD4 receptors. 10, 46 Weight gain under olanzapine therapy was significantly lower for 5-HTR2C À759T-allele carriers (0.9 vs 3.9% for others within 4 weeks, P ¼ 0.011). This is in accordance with the results of several previous studies, which have shown a significant influence of this polymorphism on weight gain under olanzapine therapy. 14, [47] [48] [49] The relative weight gain increased with better response after 4 weeks (CGI(2) rating, beta ¼ À0.41; P ¼ 0.002). This is in accordance with previous short-term studies with weight gain as a marker of symptom reduction. 50, 51 Olanzapine dose or concentrations did not correlate with weight gain. Pharmacodynamic variants seem to be more important for weight gain under treatment with atypical antipsychotics than pharmacokinetic polymorphisms. This can be explained by the fact that serum levels are only an indirect measure of the drug concentration at the site of action, the central nervous system where the blood-brain barrier prevents uncontrolled access. Secondly, gene variants affecting the drug target may be much more critical for the side effects of olanzapine than the drug concentration itself.
To summarize,
(1) The CYP1A2*1F/*1F genotype exhibits significant influence (on average À22%) on olanzapine serum levels independent of the well-known effect of inducing agents such as tobacco smoke or drugs. Standard diet and controlled environment during hospitalization makes unusual exposure to other inducing agents (for example, alimentary inducers) unlikely as an explanation. This study has several limitations, as it was not designed as a randomized placebo-controlled study although it was a good reflection of natural practice. Also, patients were not evaluated for longer than 4 weeks and the influence of comedication cannot be fully measured or excluded. Studies with larger patient groups are needed to confirm the findings.
Materials and methods
Study design
Patients were recruited at the psychiatric department at Klinikum rechts der Isar, Munich, Germany. Inpatients who received olanzapine as part of their clinical treatment for at least 4 weeks were eligible for inclusion. The design of the study was open and olanzapine dosage could be adjusted individually as clinically indicated. Inclusion criteria were psychotic conditions (ICD-10: F2), mood disorders (ICD-10: F3) and other disorders making treatment with olanzapine necessary. Patients younger than 18 years, patients suffering from organic disorders (ICD-10: F0) or drug addicts (ICD-10: F1) were excluded from the study. Further exclusion criteria were breast-feeding or pregnancy. No patients admitted to hospital by law or authority direction were included in the study. The study was approved by the local ethics committee and followed the principles of the Helsinki declaration. Patients were informed of the aims of the study and gave written consent, which could be withdrawn at any time. The treating physician and the patients were blind to genotype and serum concentrations.
Patient data including demographic data, smoking habits, weight, diagnosis, medical anamnesis as well as drug treatment and length of hospitalization were determined at admission to hospital, after 4 weeks and at dismissal in structured interviews and collected from medical charts. Changes in drug therapy as well as concomitant medication were recorded. Psychopathological state and response were assessed on admission to hospital as baseline and 4 weeks thereafter by means of the PDS self-rating scale 52 and the clinical global impressions severity (CGI1) and change (CGI2) ratings. The adverse drug events were assessed after 4 weeks of therapy according to a varied version of DOTES. 53 DOTES is organized in five clusters: cluster a (mental side effects), cluster b (neuromuscular symptoms), cluster c (gastrointestinal symptoms), cluster d (cardiovascular symptoms) and cluster e (other symptoms). The treating psychiatrist gave a rating for the 30 single items and an overall rating of side effects (0 ¼ none, 1 ¼ mild, 2 ¼ moderate, 3 ¼ marked). The score sum and the overall rating were used for side-effect evaluation. The side effects were evaluated as 'positive' for an overall side-effect rating of moderate/ marked and if probably caused by olanzapine.
Serum concentrations
Steady-state serum samples (after at least 1 week at a fixed olanzapine dose, 12-14 h postdose in week 4 of olanzapine treatment) were available for 73 patients and were measured by tandem mass spectrometry (LC/MS/MS) modified from Kirchherr et al. 54 with a LLOQ of 2.5 ng ml À1 . Commercial control samples (Chromsystems GmbH, München, Germany) containing 29 or 101 ng ml À1 were found to be 100 ± 8%. Within the calibration range, average coefficients of variation were 5.0% for intraassay and 5.7% for interassay comparisons, respectively, whereas average deviations from spiked concentrations ranged from À3.1 to 4.7%.
Genotyping
Polymorphism known to be linked to treatment response (DRD2 À141Ins/Del, DRD2 Taq1A, DRD3 Ser9Gly, 5-HTRA T102C, 5-HT6 T267C) [4] [5] [6] [7] or weight gain (5-HTRC C-759T, ADR2A C-1291G, GNB3 C825T) 9-14 of atypical antipsychotics were examined. Moreover, the 5-HTR2A intron 2 G/A (rs7997012) was examined. 8 DNA samples were available for 124 patients. The CYP1A2*1F polymorphism (rs762551) is a common C to A transition in intron 1 of the CYP1A2 gene at position 734 downstream of the first transcribed nucleotide and termed C-163A according to the human cytochrome P450 (CYP) Allele Nomenclature Committee with the A allele being the highly inducible allele. Genotyping was carried out as described elsewhere. 55 5-HTRC C-759T and 5-HTR2A (rs7997012) genotypes were determined by realtime PCR cross-validated with restriction fragment length polymorphism (RFLP) methods. A published TaqMan assay 56 was adapted for the ADR2A C-1291G (rs1800544) polymorphism. The 5-HTRA T102C, 57 and Spearman's rank correlation coefficients. Dose-/body weight-normalized serum concentrations and weight gain (%) were compared by two-tailed t-test or ANOVA. The combined effects of possible covariates (dose, diagnosis, age, gender, height, weight, smoking, duration of illness, genotypes and comedication) on the serum concentration were investigated using multiple linear regression analysis. The possible covariates were entered stepwise into the model; a parameter was included when the 95% confident interval of its standard error did not include zero and the objective function value was decreased by more than 3.84, which corresponds to a significance (probability) of the F value o0.05. Odds ratio and Cohen's d effect size were calculated to quantify the strength of the significant relationships (with Cohen's d40.8 considered as large effect and 40.5 as medium effect 62 ).
